


ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease

20-week study with four doses of ALZ-101/placebo on week 0, 4, 8 and 16 with follow-up period of 48 weeks



*according to National Institute of Aging – Alzheimer's Association (NIA-AA)